A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
9. Mai 2016 aktualisiert von: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Diabetic Painful Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension
The purpose of this study is to evaluate the analgesic efficacy, safety and tolerability of multiple doses of JNJ-42160443 when administered as a single, subcutaneous injection every 28 days to patients with diabetic painful neuropathy (a disease condition in diabetic patients that affects all peripheral nerves including pain fibers, motor neurons and the autonomic nervous system).
Studienübersicht
Status
Beendet
Bedingungen
Detaillierte Beschreibung
This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), dose-ranging study (study carried out at different doses) to evaluate the analgesic efficacy, safety, and tolerability of multiple doses of JNJ-42160443 in patients with neuropathic pain, followed by a double-blind safety extension and an open-label (all people know the identity of the intervention) safety extension.
The study will consist of 5 sequential phases: 1) screening, 2) a 12-week double-blind efficacy, 3) a 40-week double-blind safety extension, 4) a 52-week open-label safety extension, and 5) a 26-week post-treatment/follow-up.
After the screening phase, patient randomization will be stratified by current pain medication use (patients who are currently using or who are not currently using permitted pain medication).
The planned doses for the double-blind efficacy phase and double blind safety extension phase are placebo, JNJ-42160443 1, 3, or 10 mg administered as a single, subcutaneous injection every 28 days.
Safety assessment will include adverse events, injection site evaluations, clinical laboratory tests, electrocardiogram, vital signs, physical examinations, neurological examinations, and joint safety which will be monitored throughout the study.
The total study duration (including all the 5 phases) will be approximately 131 weeks.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
77
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Arkansas
-
Jonesboro, Arkansas, Vereinigte Staaten
-
-
California
-
Fresno, California, Vereinigte Staaten
-
La Jolla, California, Vereinigte Staaten
-
Long Beach, California, Vereinigte Staaten
-
Redondo Beach, California, Vereinigte Staaten
-
Tustin, California, Vereinigte Staaten
-
Walnut Creek, California, Vereinigte Staaten
-
-
Florida
-
Bradenton, Florida, Vereinigte Staaten
-
Palm Beach Gardens, Florida, Vereinigte Staaten
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten
-
-
New York
-
Albany, New York, Vereinigte Staaten
-
Syracuse, New York, Vereinigte Staaten
-
-
North Carolina
-
Winston Salem, North Carolina, Vereinigte Staaten
-
Winston-Salem, North Carolina, Vereinigte Staaten
-
-
Ohio
-
Toledo, Ohio, Vereinigte Staaten
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten
-
-
South Carolina
-
Greer, South Carolina, Vereinigte Staaten
-
-
Tennessee
-
Tullahoma, Tennessee, Vereinigte Staaten
-
-
Texas
-
Austin, Texas, Vereinigte Staaten
-
Houston, Texas, Vereinigte Staaten
-
Plano, Texas, Vereinigte Staaten
-
San Antonio, Texas, Vereinigte Staaten
-
-
Washington
-
Renton, Washington, Vereinigte Staaten
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Chronic neuropathic pain (pain persistent for greater than 6 months) that is moderate to severe in the opinion of the investigator
- Currently taking neuropathic pain medication limited to maximal allowed doses according to guidelines provided, but are not adequately controlled by standard of care
- Currently not taking neuropathic pain medications because they are intolerable to, or not willing to use, standard of care
- Mean average pain intensity score of at least 5, but less than 10, over 7 consecutive days on an 11-point numerical rating scale
- Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus
- Required to have stable glycemic control
Exclusion Criteria:
- Patients with severe diabetic neuropathy defined by severe autonomic dysfunction or blood pressure instability Separate pain condition (e.g., joint osteoarthritis) that is more severe than their pain due to their diagnosis of Diabetic Peripheral Neuropathy
- Patients with evidence of another neuropathic pain not under the study, such as pain resulting from post-traumatic neuralgia, post-surgical neuropathy, complex regional pain, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, Human Immunodeficiency Virus (HIV) infection
- Major surgeries, trauma, and non-healing wounds/ulcers within 3 months prior to study medication
- History of severe traumatic brain injury within the past 15 years
- Other peripheral neuropathy, parasthesia or dyesthesia or previously diagnosed neurological condition causing these symptoms not related with diabetic painful neuropathy under study
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: JNJ-42160443 (1 mg)
JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
|
Experimental: JNJ-42160443 (3 mg)
JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
|
Experimental: JNJ-42160443 (10 mg)
JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
|
|
Placebo-Komparator: Placebo
Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
|
Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Average pain intensity
Zeitfenster: Baseline to Week 13
|
The mean of the daily evening assessment of average pain intensity is measured by using 11-point numerical rating scale (NRS), where 0 = no pain and 10 = pain as bad as the patient can imagine.
|
Baseline to Week 13
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pain at its worst
Zeitfenster: Baseline to Week 13
|
The assessment of pain at its worst in the past 24 hours will be performed once daily, in the evening, using an 11-point numerical rating scale (NRS), where 0 = no pain and 10 = pain as bad as the patient can imagine.
|
Baseline to Week 13
|
|
Brief Pain Inventory
Zeitfenster: Up to Week 105
|
The Brief Pain Inventory short form (BPI-SF) includes 4 items assessing pain intensity (pain intensity subscales) and 7 items assessing how much pain has interfered with daily activities (pain interference subscales).
The intensity of pain is assessed with 4 items using an 11-point NRS from 0 = no pain to 10 = higher severity of pain.
This assessment will be conducted on daily basis.
|
Up to Week 105
|
|
Neuropathic pain symptom inventory (NPSI)
Zeitfenster: Up to Week 105
|
The NPSI contains 12 questions designed to evaluate the different symptoms of neuropathic pain.
The questions make up the following 5 subscales: burning (superficial) spontaneous pain, pressing (deep) spontaneous pain, paroxysmal pain, evoked pain and paresthesia/dysesthesia. Subscale scores can be derived from averaging the scores from the item scores that make up the subscales, ranging from 0 to 10.
A total intensity score is the sum of the subscale scores, ranging from 0 to 100.
Higher scores indicate worse pain.
This assessment will be conducted on daily basis.
|
Up to Week 105
|
|
Patient Global Impression of Change (PGIC)
Zeitfenster: Up to week 105
|
The patient will be asked to rate their change in their neuropathic pain with the following responses: very much improved, much improved, minimally improved, not changed, minimally worse, much worse, or very much worse.
This assessment will be conducted on daily basis.
|
Up to week 105
|
|
Number of patients with adverse events
Zeitfenster: Up to week 105 and 26 weeks after the last dose of study medication
|
Up to week 105 and 26 weeks after the last dose of study medication
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. November 2009
Primärer Abschluss (Tatsächlich)
1. Juni 2011
Studienabschluss (Tatsächlich)
1. Juni 2011
Studienanmeldedaten
Zuerst eingereicht
8. Oktober 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
8. Oktober 2009
Zuerst gepostet (Schätzen)
9. Oktober 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
3. Juni 2016
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
9. Mai 2016
Zuletzt verifiziert
1. Mai 2016
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CR016438
- 42160443NPP2002 (Andere Kennung: Johnson & Johnson Pharmaceutical Research and Development, L.L.C.)
- 2008-007676-13 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .